Temple
PrivateLast Round
Seed
Feb 27, 2026
Est. Valuation
$190M
Total Funding Raised
$54M
Company Overview
Temple operates in Healthcare & Life Sciences and is based in Gurgaon. Its latest recorded funding round was a Seed round in February 2026.
Temple is a health technology company developing a wearable device for elite athletes that measures cerebral blood flow and other physiological metrics.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Consumer Electronics, Sports & Fitness, Health IoT
Business Model
B2C
Customer Profile
Hardware + Subscription
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Temple Comparables
Compare Temple with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Mendi Innovations | 77% | |
| Ultrahuman | 74% | |
| Whoop | 66% |
For institutional investors. Book with your work email.
Temple Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Temple Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aaroh Capital | Seed |
| Steadview Capital | Seed |
| Peak XV Partners | Seed |
| Dharana Capital | Seed |
| Vy Capital | Seed |
| Info Edge Ventures | Seed |
Recent news
Latest coverage and updates
- partners_withSep 14, 2026
Temple works with SSIAR, the Art of Living Foundation’s research division, to study the effects of different meditation practices using Entropy to examine physiological changes, with study results due for publication soon, on Sep 14th '26.
- partners_withSep 14, 2026
On Sep 14th '26, Temple partners with Art of Living to study the effects of different meditation practices using Entropy, a biomarker that measures the body's (para)sympathetic state.
- is_developingSep 14, 2026
Temple is developing a wearable device that collects physiological and wellness data for general wellness and informational purposes, not medical diagnosis or treatment.
- hiresAug 28, 2026
On Aug 27th '26, Temple plans to hire Roy as Head of Science as part of its acquisition of London-based Longevous.
- is_developingAug 27, 2026
Temple is developing a wearable that collects signals related to cerebral blood flow, oxygenation and heart rate and monitors changes linked to exercise, sleep, recovery and meditation; it plans to begin taking preorders soon, with shipments expected before the end of 2026.
For institutional investors. Book with your work email.
Temple Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Temple's valuation, stock price, and market status.
Is Temple a public or private company?
Temple is a private company.
What is the current stock price of Temple?
Temple is a private company, so its shares have no public market price. Caplight tracks Temple's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Temple worth (valuation)?
Temple's valuation is estimated at $190.0M based on funding round data.
Can I buy Temple stock?
Temple shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Temple's last funding round?
Temple's most recent funding round was Seed on February 27, 2026.
Who are the main investors in Temple?
Key investors in Temple include Aaroh Capital, Steadview Capital, Peak XV Partners, Dharana Capital, Vy Capital.
Will Temple IPO soon?
No public IPO plans have been announced for Temple.
How can I track Temple secondary market activity?
Caplight tracks bids, offers, and trades in Temple's shares on secondary markets.